Siddharth Mittal appointed as MD and CEO of Syngene International effective July 1, 2026

Ceo ResignedCeo Appointed ExternalManagement Changes View source PDF Explain this filing

SYNGENE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹431.05

prior close

₹434.90

announcement price

After-mkt

timing

Nifty Smallcap 250market+1.0%+1.1% vs market

Healthcare Research Analytics & Technology peers, median of 5sector+0.1%+2.0% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Smallcap 250 and 2.0 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.5

15m

+0.5

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.1+1.0+1.1+0.1+2.0

Next day

+2.3+1.1+1.2-0.2+2.6

-0.0+1.6-1.6+1.7-1.7

-1.9+0.9-2.8+0.0-2.0

-4.0-1.1-2.9+0.0-4.1

-3.5+0.4-3.9-1.7-1.8

-2.3+2.1-4.3-0.0-2.2

15d

-6.1-0.8-5.2-2.6-3.5

-6.7+2.1-8.8+5.8-12.6

-7.5+2.6-10.1+16.4-23.9

-17.2-0.8-16.4+11.5-28.7

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Siddharth Mittal has been appointed as Managing Director and CEO of Syngene International effective July 1, 2026, succeeding Peter Bains whose tenure ended June 30, 2026. Mittal joins from Biocon Limited where he served as MD and CEO, and earlier as CFO for 13 years. He led Biocon's GLP-1 portfolio commercialization globally. Syngene, a global CRDMO with over 8,300 employees, works with around 400 global customers.

Likely market impact

Smooth transition as an experienced executive from Biocon group takes charge. Investors will watch growth recovery and execution.